WHO Grade II Ependymomas of the Fourth Ventricle in Adults – Single Institution Experience

Česká verzia

Authors: A. Štekláčová; O. Bradáč; V. Beneš
Authors place of work: Neurochirurgická klinika 1. LF UK a ÚVN – VFN Praha
Published in the journal: Cesk Slov Neurol N 2014; 77/110(6): 753-759
Category: Short Communication

Práce byla podpořena grantem IGA MZ NT 12254-5 a Institucionální podporou MO 1012.

Summary

Introduction:
Surgical resection is a generally accepted standard treatment modality in GII posterior fossa ependymomas in adults, while the role of adjuvant radiotherapy remains unclear. The purpose of this study was to evaluate local control of tumor growth and clinical outcome of patients after surgical treatment of GII fourth ventricle ependymomas.

Material and methods:
We conducted a retrospective study of 15 adult patients (seven males and eight females) with histologically confirmed GII fourth ventricular ependymoma between January 2001 and December 2011.

Results:
Gross total resection was achieved in 12 patients, none of them received adjuvant treatment after the initial surgery. Median follow-up after GTR was 51 months (min. – max.; 11–123 months). One patient showed radiographic signs of tumor recurrence and was re-operated 51 months after the initial surgery. Remaining patients were without any signs of tumor recurrence. After the surgery, a new neurological deficit occurred in two patients. Two of the three patients after subtotal tumor resection showed residual mass progression after 11 and 16 months postoperatively, one of them was re-operated 27 months after the initial surgery. Adjuvant radiotherapy was indicated in both re-operated patients.

Conclusion:
According to our data, gross total resection is effective and safe treatment of GII fourth ventricle ependymomas. Adjuvant radiotherapy should be reserved for the cases where complete removal of tumor mass is not possible and residual tumor is growing, or after repeated resection.

Key words:
ependymoma – adult – fourth ventricle – posterior fossa surgery – survival recurrence – radiotherapy

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Zdroje

1. Reni M, Brandes AA, Vavassori V, Cavallo G, Casagrande F, Vastola F et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 2004; 100(6): 1221– 1229.

2. Guyotat J, Signorelli F, Desme S, Frappaz D, Madarassy G, Montange MF et al. Intracranial ependymomas in adult patients: analyses of prognostic factors. J Neurooncol 2002; 60(3): 255– 268.

3. Ernestus RI, Schroder R, Stutzer H, Klug N. The clinical and prognostic relevance of grading in intracranial ependymomas. Br J Neurosurg 1997; 11(5): 421– 428.

4. Korshunov A, Golanov A, Sycheva R, Timirgaz V. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 2004; 100(6): 1230– 1237.

5. Metellus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Gouvernet J et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 2007; 130(5): 1338– 1349.

6. Metellus P, Guyotat J, Chinot O, Durand A, Barrie M, Giorgi R et al. Adult intracranial WHO grade IIependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol 2010; 12(9): 976– 984. doi: 10.1093/ neuonc/ noq047.

7. Rogers L, Pueschel J, Spetzler R, Shapiro W, Coons S,Thomas T et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg 2005; 102(4): 629– 636.

8. Mirzadeh Z, Bina R, Kusne Y, Coons SW, Spetzler RF,Sanai N. Predictors of functional recovery in adults with posterior fossa ependymomas. J Neurosurg 2014; 120(5): 1063– 1068. doi: 10.3171/ 2014.1.JNS131590.

9. Aizer AA, Ancukiewicz M, Nguyen PL, Macdonald SM,Yock TI, Tarbell NJ et al. Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study. J Neurooncol 2013; 115(3): 411– 419. doi: 10.1007/ s11060-013-1237-9.

10. Guyotat J, Metellus P, Giorgi R, Barrie M, Jouvet A, Fevre-Montange M et al. Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients. Acta Neurochir (Wien) 2009; 151(8): 947– 960. doi: 10.1007/ s00701-009-0417-z.

11. Kawabata Y, Takahashi JA, Arakawa Y, Hashimoto N. Long-term outcome in patients harboring intracranial ependymoma. J Neurosurg 2005; 103(1): 31– 37.

12. McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg 2009; 110(4): 725– 729. doi: 10.3171/ 2008.9.JNS08117.

13. Bailey P, Cushing H. Classification of tumours of the glioma group on a histogenetic basis with a correlated study of prognosis. Br J Surg 1926; 14(55): 554– 555.

14. Fisher ER, Hazard JB, Gardner WJ. Intracranial ependymoma; clinicopathologic observations. Cleve Clin Q 1951; 18(4): 260– 269.

15. Dohrmann GJ, Farwell JR, Flannery JT. Ependymomas and ependymoblastomas in children. J Neurosurg 1976; 45(3): 273– 283.

16. Watanabe E, Schramm J, Strauss C, Fahlbusch R. Neurophysiologic monitoring in posterior fossa surgery. II. BAEP-waves I and V and preservation of hearing. Acta Neurochir (Wien) 1989; 98(3– 4): 118– 128.

17. Kawaguchi M, Ohnishi H, Sakamoto T, Shimizu K, Touho H, Monobe T et al. Intraoperative electrophysiologic monitoring of cranial motor nerves in skull base surgery. Surg Neurol 1995; 43(2): 177– 181.

18. Schramm J, Watanabe E, Strauss C, Fahlbusch R. Neurophysiologic monitoring in posterior fossa surgery. I. Technical principles, applicability and limitations. Acta Neurochir (Wien) 1989; 98(1– 2): 9– 18.

19. Nelson KR, Phillips LH. Neurophysiologic monitoring during surgery of peripheral and cranial nerves, and in selective dorsal rhizotomy. Semin Neurol 1990; 10(2): 141– 149.

20. Swanson EL, Amdur RJ, Morris CG, Galloway TJ, Marcus RB jr, Pincus DW et al. Intracranial ependymomas treated with radiotherapy: long-term results from a single institution. J Neurooncol 2011; 102(3): 451– 457. doi: 10.1007/ s11060-010-0344-0.

21. Vitanovics D, Balint K, Hanzely Z, Banczerowski P, Afra D. Ependymoma in adults: surgery, reoperation and radiotherapy for survival. Pathol Oncol Res 2010; 16(1): 93– 99. doi: 10.1007/ s12253-009-9194-5.

22. Oya N, Shibamoto Y, Nagata Y, Negoro Y, Hiraoka M. Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure. J Neurooncol 2002; 56(1): 87– 94.

23. Reni M, Gatta G, Mazza E, Vecht C. Ependymoma. Crit Rev Oncol Hematol 2007; 63(1): 81– 89.

24. Ferrante L, Mastronardi L, Schettini G, Lunardi P, Fortuna A. Fourth ventricle ependymomas. A study of 20 cases with survival analysis. Acta Neurochir (Wien) 1994; 131(1– 2): 67– 74.

25. Boström A, Boström J, Hartmann W, Pietsch T, Feuss M, von Lehe M et al. Treatment results in patients with intracranial ependymomas. Cent Eur Neurosurg 2011; 72(3): 127– 132. doi: 10.1055/ s-0031-1273745.

26. Stauder MC, Ni Laack N, Ahmed KA, Link MJ, Schomberg PJPollock BE. Stereotactic radiosurgery for patients with recurrent intracranial ependymomas. J Neurooncol 2012; 108(3): 507– 512. doi: 10.1007/ s11060-012-0851-2.

27. Kano H, Niranjan A, Kondziolka D, Flickinger JC, Lunsford LD. Outcome predictors for intracranial ependymoma radiosurgery. Neurosurgery 2009; 64(2): 279– 287. doi: 10.1227/ 01.NEU.0000338257.16220.F7.

28. Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR. Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol 2010; 12(8): 862– 870. doi: 10.1093/ neuonc/ noq009.

29. McLaughlin MP, Marcus RB jr, Buatti JM, McCollough WM, Mickle JP, Kedar A et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 1998; 40(4): 845– 850.

30. Schild SE, Nisi K, Scheithauer BW, Wong WW, Lyons MK, Schomberg PJ et al. The results of radiotherapy for ependymomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 1998; 42(5): 953– 958.

31. Buchvald P, Suchomel P, Kaiser M. Chirurgická léčba ependymomů krční a horní hrudní míchy. Cesk Slov Neurol N 2007; 70/ 103(2): 196– 200.

32. McGuire CS, Sainani KL, Fisher PG. Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer 2009; 52(1): 65– 69. doi: 10.1002/ pbc.21806.

33. Shu HK, Sall WF, Maity A, Tochner ZA, Janss AJ, Belasco JB et al. Childhood intracranial ependymoma: twenty-year experience from a single institution. Cancer 2007; 110(2): 432– 441.

34. Lyons MK, Kelly PJ. Posterior fossa ependymomas: report of 30 cases and review of the literature. Neurosurgery 1991; 28(5): 659– 664.

35. Mansur DB, Perry A, Rajaram V, Michalski JM, Park TS, Leopard JR et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys 2005; 61(2): 387–391.

36. Donahue B, Steinfeld A. Intracranial ependymoma in the adult patient: successful treatment with surgery and radiotherapy. J Neurooncol 1998; 37(2): 131–133.